Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nautilus Biotechnology Inc NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform... see more

Bullboard (NDAQ:NAUT)

View:
Post by MikeTesteron Aug 03, 2024 7:39am

Nautilus Biotechnology: Pioneering a Revolutionary Proteomic

https://beyondspx.com/2024/08/02/nautilus-biotechnology-pioneering-a-revolutionary-proteomics-platform/
Post by whytestockson Apr 30, 2024 11:45am

Nautilus Biotechnology Reports First Quarter 2024 Financial

Breaking News: $NAUT Nautilus Biotechnology Reports First Quarter 2024 Financial ResultsSEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities